Influenza vaccination in pregnancy among a group of remote dwelling Aboriginal and Torres Strait Islander mothers in the Northern Territory: The 1+1 Healthy Start to Life study

Lisa McHugh, Michael J Binks, Yu Gao, Ross M Andrews, Robert S Ware, Tom Snelling and Sue Kildea.

# Summary

We found uptake of inactivated influenza vaccine (IIV) in pregnancy in remote-living Aboriginal and Torres Strait Islander women from the NT of Australia was 0% for the pre-influenza A(H1N1)pandemic period (A(H1N1)pdm09) from 2003 to 2006, and remained unacceptably low (7%) for the post-influenza A(H1N1)pdm09 period (>2009–2011). Although IIV was routinely recommended for pregnant women throughout the entire eight year study period, vaccine uptake was extremely low among the 697 pregnancies in our study, particularly in women with known comorbidities and/or high risk factors.

# Abstract

Remote-living Aboriginal and Torres Strait Islander women experience a higher burden of influenza infection during pregnancy than any other Australian women. Despite recommendations of inactivated influenza vaccination (IIV) in pregnancy, uptake and safety data are scarce for this population. We examined uptake of IIV in pregnancy and report adverse birth outcomes amongst a predominantly unvaccinated group of remote-living Aboriginal and Torres Strait Islander women from the Northern Territory (NT), using data from the 1+1 Healthy Start to Life study. Data were deterministically linked with the NT Immunisation Register to ascertain IIV exposure in pregnant women during 2003–2006 and 2009–2011 inclusive. Overall, IIV uptake in pregnancy was 3% (n=20/697 pregnancies); 0% (0/414) pre-influenza A(H1N1)pdm09 and 7% (20/293) post-influenza A(H1N1)pdm09 (2009–2011). Vaccine uptake was poor in this cohort and it is unclear at what stage this policy failure occurred. Women with known comorbidities and/or high risk factors were not targeted for vaccination. Much larger study participant numbers are required to validate between group comparisons but there was no clinically nor statistically significant difference in median gestational ages (38 weeks for both groups), mean infant birthweights (3,001 g unvaccinated vs 3,175 g IIV vaccinated), nor birth outcomes between the few women who received IIV in pregnancy and those who did not. There were no stillbirths in women who received an IIV in pregnancy.

Keywords: Influenza, remote, Northern Territory, pregnancy, birth outcomes, vaccination, uptake, Aboriginal, Australia

# Introduction

Pregnant women are a high priority for seasonal inactivated influenza vaccination (IIV) worldwide.1 Pregnant women and infants bore a disproportionately high burden of illness during the 2009 influenza A (H1N1) pandemic (influenza A(H1N1)pdm09),2,3 where 30–50% of women of child-bearing age who died were pregnant.4,5 The disease burden from influenza infection was particularly high amongst pregnant Indigenous women in Canada, the Americas and the Pacific, including Australia,6–8 where the risk of severe disease and death from influenza A(H1N1)pdm09 was 3–12 times higher than for non-Indigenous populations.7,9

Aboriginal and/or Torres Strait Islander (hereafter respectfully referred to as Aboriginal) women and their infants continue to experience a higher burden of influenza infection during pregnancy and early infancy compared to non-Aboriginal Australians,10 and are disproportionately over-represented during influenza pandemics with higher rates of hospitalisations and intensive care unit (ICU) admissions.11 Australian infants younger than six months of age incur up to 320 annual hospitalisations per 100,000 population, of which one in 10 are admitted to an ICU.12,13 Laboratory-confirmed influenza notifications and average annual notification rates in Northern Territory (NT) women of child-bearing age (15–<50 years) from 2008 to 2012 also showed a marked disproportionate burden of illness in Aboriginal women compared to non-Aboriginal women of the same age group.13,14

In March 2000, a recommendation for seasonal IIV was added to the Australian National Immunisation Program (NIP) for all women who would be pregnant during the influenza season, regardless of trimester of pregnancy, and the program became funded (free) in 2010.15 The safety of maternal vaccination and vaccine provider recommendation are known to be the key drivers influencing the uptake of IIV in pregnancy.16,17 Given there is a disproportionate disease burden from influenza infection amongst Aboriginal Australians,18 the available data on seasonal IIV uptake and safety for pregnant Aboriginal women is scarce, particularly for those women living in remote areas where the disease burden may be even greater. A World Health Organization (WHO) report published in 2017, examining the epidemiology of influenza in pregnancy, found robust safety data in the form of randomised controlled trials (RCTs) were still lacking, with birth outcomes reported from observational studies conflicting and at risk of bias.19 A separate review of the safety of immunisation during pregnancy by the WHO has also recommended that further safety evidence is needed for high-risk groups and local Indigenous populations.20

The primary aim of this study was to ascertain seasonal IIV uptake in pregnancy amongst a cohort of remote-living Aboriginal women in the NT. Subject to adequate IIV uptake, the secondary aim was to compare key birth outcomes between IIV-vaccinated and unvaccinated pregnant women.

# Methods

## Study design

We conducted retrospective cohort analyses using data collected from the ‘1+1 Healthy Start to Life’ study (1+1HS).21 Briefly, the 1+1HS study was designed to examine the utilisation and quality of health services and subsequent maternal and infant health outcomes of Aboriginal women residing in remote communities in the NT over two time periods: before (2003–2006) and after (2009–2011) a significant service redesign. Throughout the study period, pregnant women were routinely transferred to Royal Darwin Hospital (RDH) to birth their baby. Those mothers who were ≥20 weeks gestation with a singleton infant that weighed ≥400 grams (g) at birth were included. Women who birthed more than one infant within the study period were identified, and women pregnant with twins were excluded from the data analysis on adverse birth outcomes. Maternal and infant community health centre and regional hospital records were manually audited for each study participant, then linked with demographic, comorbidity and risk factor data, health utilisation and cost and maternal and infant health outcomes. This became the final 1+1HS dataset.

Identifiable 1+1HS data were then deterministically linked with the NT Immunisation Register (NTIR) using the maternal identification number (ID) as the common identifier to confirm and validate maternal vaccination status in pregnancy. The NTIR is a population-based dataset of all immunisations administered in the NT. Clinical record checks were conducted manually for records where discrepancies occurred between the 1+1HS and NTIR datasets. Data cleaning was conducted to identify duplicates, multiple births and repeat birth, non-twin siblings. Missing data were treated as such.

## Maternal vaccine exposure

The primary exposure of interest was any influenza vaccination given during pregnancy, defined as a vaccine received between the first day (date) of the last normal menstrual period and the date of birth of the infant. Vaccination status in pregnancy was determined by using the date of vaccination, gestation in weeks at birth of the infant and the date of birth of the infant. Records of IIV obtained from the NTIR were dropped if the dates of IIV did not correlate with IIV during pregnancy or during the 12 months prior. Brand names and dosages of any vaccines received by each woman were ascertained, however batch-specific details were not available. The number of days from receipt of IIV in pregnancy until birth of the infant was recorded.

## Birth outcomes

The primary birth outcomes of interest were: preterm births—infants born >20 weeks gestation, >400 g and <37 completed weeks’ gestation;22 low birth weight (LBW)—any infant born >20 weeks and <2,500 g;23 and small for gestational age (SGA)—infant birthweight <10th percentile calculated using Australian specific national birthweight percentiles by sex and gestational age.24 Maternal risk factors for adverse birth outcomes were recorded for all study participants (Box 1).

**Box 1: Maternal comorbidities and risk factors collected from 1+1HS study participants, 2003–2011.**

* Attended antenatal care in the 1st trimester (Y/N)
* Smoking in pregnancya (Y/N)
* Pregnancy complicationb
* Previous poor obstetric outcomec
* Rheumatic heart disease
* Cardiac condition
* Diabetesd
* Renal disease
* Asthma
* Maternal anaemia

a Recorded at first antenatal visit and at 36 weeks gestation

b Includes threatened preterm labour, preterm rupture of membranes, antepartum haemorrhage, placental abruption, placenta praevia, urinary tract infection (UTI), sexually transmitted infection (STI), gestational hypertension, pre-eclampsia

c Includes previous history of preterm birth, stillbirth, neonatal death (in multiparous women)

d Includes type 1, type 2 and gestational diabetes


## Data analysis

Data from the NTIR were merged with the 1+1HS dataset using the maternal identifier to calculate the proportion of women who received an IIV in pregnancy, by study year. Demographic, comorbidity and risk factor characteristics of mother-infant pairs were summarised and compared between women who received an IIV during pregnancy and mothers who did not. Proportions were calculated; chi2 analyses for binary and categorical variables; and, depending on the distribution of the data, t-tests and ranksum analyses to calculate means and medians for continuous variables. We conducted Cox proportional-hazard ratio analyses for time-dependent birth outcomes using the continuous variable ‘gestational age’ as the time-scale variable. Compared to the unexposed group (unvaccinated pregnant women), in the exposed group (women who received IIV in pregnancy), the number of days from receipt of IIV in pregnancy until the birth of the infant was used to calculate effect estimates. Effect estimates are presented as crude hazard ratios (HR) with 95%CI. Data were analysed using Stata v.14.1 (StataCorp, College Station, Texas).

# Results

There were 576 women with 697 pregnancies and 697 individual infants who were included in the cohort over the two observation periods: 1 December 2003 – 31 December 2006 and 1 January 2009 – 31 June 2011 (Figure 1). There were 121 mothers (17%) who birthed more than one infant (repeat births).

**Figure 1: Study participants from 1+1 Healthy Start study, by IIV vaccination status, Northern Territory, Australia, 2003–2012.**



There were nine women who birthed twins (n=18 infants), and none of these women received IIV in pregnancy. These women were henceforth excluded from further data analysis due to known confounding effects for preterm birth, LBW and SGA outcomes. Data linkage with the NTIR found a matching record for all 1+1HS study participants apart from three, who were excluded. A further six women who received dTpa (pertussis) vaccine in pregnancy were also excluded, none of whom had received an IIV in pregnancy.

## Uptake

Of the 697 pregnancies, 20 women (3%) received IIV in pregnancy and 677 (97%) women were unvaccinated. The median time from receipt of IIV until birth of the baby was 9 weeks (range 1.9–22.6), or in days 63 (range 13–158). Ten women received IIV in the third trimester of pregnancy, all of whom were vaccinated approximately two weeks before the birth of the infant. Nine women received IIV in the second trimester and one in the first trimester. Seasonal IIV uptake in pregnancy during 2003–2006 inclusive (pre influenza A(H1N1)pdm09) was zero (0/414). In 2009, six IIVs were given from July to November, commencing two months after the first case of influenza was detected in the NT. During 2009–2011 inclusive (post-influenza A(H1N1)pdm09), uptake was 20/293 (7%). There were no data collected in 2007 and 2008 (Table 1).

**Table 1: IIV uptake pre- and post-influenza A(H1N1)pdm09 in 1+1HS study participants, Northern Territory, Australia, 2003–2011.s**

| Year of birth | Number of births | N vaccinated with IIV in pregnancy | % |
| --- | --- | --- | --- |
| 2003 | 1 | 0/1 | (0%) |
| 2004 | 122 | 0/122 | (0%) |
| 2005 | 142 | 0/142 | (0%) |
| 2006 | 139 | 0/139 | (0%) |
| 2007 | Data not collected | n/a |  |
| 2008 | Data not collected | n/a |  |
| 2009 | 44 | 6/44 | (14%) |
| 2010 | 153 | 1/153 | (<1%) |
| 2011 | 96 | 13/96 | (14%) |
| **Total** | **697** | **20/697** | **(3%)** |

## Maternal characteristics, comorbidities and risk factors

The median maternal age of study participants at birth of their infant was 24 years for women who received IIV in pregnancy (range in years 13–41) and unvaccinated pregnant women (range in years 18–41); 31% were primiparous women and 53% of infants born were male. There were 281 women (42%) who presented for antenatal care in the first trimester, with 11 (4%) of these receiving IIV in pregnancy. The median gestation in weeks at first presentation for antenatal care was 13 (range 7–28) for women who received IIV in pregnancy and 16 (range 0–40) for unvaccinated pregnant women. Overall, 22% of multiparous women had a prior history of a poor obstetric outcome (either preterm birth, stillbirth or neonatal death) with six (4%) of these having received IIV in pregnancy. Other differences in maternal demographics, comorbidities and risk factors between women who received IIV in pregnancy are shown in Table 2.

**Table 2: Maternal characteristics, comorbidities and risk factors of 1+1HS study participants, and percentage who received IIV in pregnancy, Northern Territory, Australia, 2003–2012.**

| Characteristics | Total  n (%) | Vaccinateda  influenza n (%) |
| --- | --- | --- |
| Twin pregnancy | 9/594 (2%) | 0/9 (0%) |
| Parity (primiparous) | 217/697 (31%) | 5/217 (2%) |
| Antenatal care 1st trimester (Y/N) b | 281/697 (42%) | 11/281 (4%) |
| Smoking in pregnancy when recorded, (Yes) at 36wks | 113/199 (57%) | 6/113 (5%) |
| Previous poor obstetric outcomec | 152/697 (22%) | 6/152 (4%) |
| Rheumatic heart disease | 41/697 (6%) | 3/41 (7%) |
| Cardiac condition | 62/697 (9%) | 1/62 (2%) |
| Diabetesd | 46/697 (7%) | 2/46 (4%) |
| Renal disease | 20/697 (3%) | 0/20 (0%) |
| Asthma | 9/697 (1%) | 0/9 (0%) |
| Maternal anaemia | 414/697 (59%) | 13/414 (3%) |
| Pregnancy complicatione | 374/697 (54%) | 11/374 (3%) |

Note: denominators differ due to missing data.  
a number n (%) who received IIV in pregnancy that had comorbidity/risk factor  
b Self-reported response at 1st antenatal visit  
c Includes previous history of preterm birth, stillbirth, neonatal death (in multiparous women)  
d Includes type 1, type 2 and gestational diabetes  
e Includes threatened preterm labour, preterm rupture of membranes, antepartum haemorrhage, placental abruption, placenta praevia, UTI, STI, gestational hypertension, pre-eclampsia

## Birth outcomes

Low uptake of IIV during pregnancy limited the capacity for meaningful comparisons of birth outcomes between unvaccinated women (the referent group) and the small number of women who were vaccinated in pregnancy. The median gestational age at birth of the infant was 38 weeks (range 21–42 weeks) for both the unvaccinated and vaccinated pregnant women, with a small and neither clinically relevant or statistically significant difference in mean birthweights (3,001 g vs 3,175 g [95%CI -467 g, 119 g, p=0.24]). Proportions of preterm births and LBW were similar between the unvaccinated and vaccinated group (Table 3), though there were proportionally more than three times as many infants born SGA in unvaccinated pregnancies, 17% (111/660), compared to 5% (1/19) of IIV vaccinated pregnancies. Our time-dependent analysis found no evidence of an increased risk of preterm births, LBW or SGA infants when comparing women who received an IIV in pregnancy with unvaccinated pregnancies (Table 3). Adjusted HRs were not conducted due to insufficient numbers of vaccinated women for the model to support adjustment on multiple factors.

****Table 3: Cox proportional-hazard ratios for birth outcomes in 1+1HS study participants, Northern Territory, Australia, 2003–2011.****

| Birth outcome | Unvaccinated Referent group 677/697 | %(97%) | Vaccinateda Influenza 20/697 | %(3%) | HRb (95%CI) |
| --- | --- | --- | --- | --- | --- |
| Gestationc (range) differences (95% CI) | 38wks (21–42 wks) |  | 38 wks (29 – 41 wks); 0 wks (-0.9, 1.39 wks) |  |  |
| Birthweightd (range) differences (95% CI) | 3001g (400 g – 5080 g) |  | 3175 g (1371 g – 4715 g); +174 g (-468 g, 118 g) |  |  |
| Preterm birth (<37 completed weeks) | 126/677 | (19%) | 4/20 | (20%) | 1.35 (0.50, 3.67) |
| Low birthweight (<2500 g) | 113/677 | (17%) | 4/20 | (20%) | 1.41 (0.52, 3.83) |
| Small for gestational age (<10th percentile) | 111/660 | (17%) | 1/19 | (5%) | 0.28 (0.04, 2.02) |

Note: denominators differ due to missing data.

a Results compared to referent (unvaccinated) group

b Hazard ratio: results are compared to referent (unvaccinated) group

c Median gestation at birth of infant

d Mean infant birthweight

# Discussion

Despite a nationally-funded seasonal IIV program targeting Aboriginal pregnant women being recommended since 2000, only 3% of the Aboriginal women in our study received an IIV vaccination during their pregnancy during 2003–2006 and 2009–2011. This very low coverage was particularly disconcerting given our study participants were women living in a remote setting with high rates of poverty and markedly high rates of smoking, comorbidities, birthing at a younger age, and pregnancy, birth and postnatal complications, similarly reported in remote-living Aboriginal women from the NT.25,26 Aboriginal women continue to incur significantly more adverse perinatal outcomes compared to other Australian women, particularly stillbirths, preterm births, SGA and LBW infants.25,27 These infants experience higher rates of morbidity and mortality and are more susceptible to vaccine-preventable infections compared to infants born at term.25,28 The long-term sequelae for Aboriginal infants who are born preterm or LBW comprises substantially higher rates of chronic diseases and hospitalisations compared to non-Aboriginal adults.25,29

The first NT case of influenza A(H1N1)pdm09 was detected on 29 May 2009.29 Coverage of IIV uptake in pregnancy was 0% in a pre influenza A(H1N1)pdm09 era (<2009). We expected uptake to be substantially higher than observed, and saw no evidence of improved or sustained vaccination coverage after a small increase during the pandemic (14%) and post pandemic (14%). It is not possible to determine whether this was a failure to report, under-ascertainment or refusal of vaccination, however similar studies have also reported low IIV uptake in pregnant Aboriginal women.30 Further, an existing vaccination record from the NTIR was detected for >98% of the participants in our study, and immunisation coverage is known to be high among Aboriginal infants from the NT.31 One study nested within a RCT examined pre- and post-influenza A(H1N1)pdm09 IIV uptake in different Aboriginal communities in the NT over a similar time period (2006–2011).30 This study found very low rates of seasonal IIV uptake (~4% verified) in pregnant Aboriginal women in a pre-influenza A(H1N1)pdm09 period (n=3/71), with verified coverage increasing to ~42% (n=28/67) in the intra-influenza A(H1N1)pdm09 period (2009–2010). Participant numbers for that study were small (N=138), with a relatively higher level of education and less high-risk factors compared to remote-living Aboriginal women from the NT.26 A NT bulletin showed IIV uptake in Aboriginal pregnant women during 2013 was ~30% (n=585/1,930) for those who birthed at RDH,32 which is where our study population birthed. Whilst this shows a substantial increase in IIV uptake in pregnancy for Aboriginal women, the breakdown of remote- and very-remote-living status was not reported, therefore uptake of IIV in pregnancy is potentially not generalisable for the whole Aboriginal population who live in the Top End, and potentially an artefact of healthy, urban and outer-regional-living Aboriginal pregnant women accessing antenatal health care programs. A small survey in 2017 from Western Australia (WA) reported 37% (n=35/94) of Aboriginal women with a known vaccination status received an IIV in pregnancy.33 The women in the WA study were largely metropolitan/urban living, and it is unclear what proportion, if any, were remote-and very remote-living. Maternal demographic characteristics, comorbidities, risk factors and adverse birth outcomes were not reported in the WA survey.

Australian literature has demonstrated that advice on maternal vaccination from a pregnant woman’s healthcare provider is the key influencer of vaccination uptake in pregnancy,17 and that if given the opportunity, Aboriginal women are accepting of IIV in pregnancy,33 particularly if community consultation and engagement with local communities is a priority.34 Providing evidence of IIV uptake, safety and effectiveness in pregnancy in a consistent, appropriate and culturally acceptable way for Aboriginal women and their families is also essential.35 Providing local support of maternal vaccination programs to antenatal healthcare workers may be critical in order to give remote-living pregnant Aboriginal women an informed, positive recommendation regarding maternal vaccination.

The 2017 Aboriginal and Torres Strait Islander Health Performance Framework report of the NT36 highlighted an important aim was to map the health needs of remote Aboriginal women and infants to the health services available, in order to address low birthweight, smoking during pregnancy and low antenatal care attendance. Addressing the high burden of respiratory illness in pregnancy, in women of childbearing age, and in young infants is also warranted in this population. Acknowledging the poor uptake of IIV we observed in our study, increasing IIV coverage in pregnancy would be a step forward, provided safety and effectiveness can be demonstrated.

The international literature on the safety of IIV in pregnancy are encouraging,37,38 but there are persistent gaps in the evidence for high-risk populations, such as remote-living Indigenous peoples, that need to be addressed. Data are lacking on the safety of vaccination in the first trimester of pregnancy, and on safety endpoints such as miscarriage, preterm births, stillbirths, LBW and SGA infants. One Australian study published in 2018 found no increased risk in preterm births, low birthweight or SGA infants in pregnant women who received a seasonal IIV compared to unvaccinated pregnant women,39 however only 3% of this national cohort (N=8,827 mother-infant pairs) were Aboriginal women. Prior to 2015, analyses were largely limited to specific vaccines used during the influenza A(H1N1) pandemic,40 and observational studies used in a meta-analysis38 were non-Indigenous women living in well-resourced populations of North America and Europe.

## Strengths and limitations

A strength of this study lies in the rich, rigorous data collection methodologies and the ability to ascertain maternal vaccination status for all study participants. Our sample size of 697 pregnancies among 582 remote-living Aboriginal women is larger than other available studies, and through data linkage rather than self-report, we were able to establish seasonal IIV uptake based on confirmed dates of vaccination. Data linkage also enabled us to improve the internal validity of the study sample. We were able to retrieve missing maternal and infant data, enabling us to identify duplicate entries and to correct illogical dates of maternal and infant births. Our small numbers of vaccinated pregnancies were unexpected and as such, are a limitation, as was the inability to report on women who suffered miscarriages <20 weeks gestation. We did however, reduce the risk of introducing immortal time bias by applying the recommended methodology for conducting time-dependent analyses.

There are currently no programs to systematically monitor the uptake, safety and effectiveness of IIV in pregnancy, so it is difficult to determine where the procedural gaps exist for remote-living Aboriginal pregnant women of the NT. Until such programs are in place, well-conducted observational studies and data linkage studies remain important, particularly for planning and in preparation for future influenza pandemics.

# Conclusion

In Australia, an operational period of a nationally recommended seasonal IIV has been in place for almost 20 years. Despite the funded IIV program targeting pregnant Aboriginal women, vaccine uptake remained <4% in our participants from remote and very remote communities in the NT across 2003–2006 and 2009–2011. Reasons for this policy failure during this time period are unknown, with further research needed. Providing evidence of the safety and effectiveness of IIV in pregnancy may contribute to the willingness of women and health care providers to implement this policy.

# Declarations

Ethics approval and consent to participate

This project was approved by the Menzies School of Health Research Human Research Ethics Committee (reference number 2016-/2710) and the Northern Territory Government Department of Health (project number 2016-0377).

# Conflict of interest

The authors declare that they have no competing interests.

# Funding

The 1+1 Healthy Start to Life study was funded by a National Health and Medical Research Council and NT Government Research and Innovation Board Project Grant (number: 422503). LMcH was supported by an Australian Postgraduate Award scholarship provided by Charles Darwin University of the Northern Territory and an Enhanced Living scholarship provided by Menzies School of Health Research as part of the Doctor of Philosophy (PhD) program.

# Authors’ contributions

LMcH cleaned and analysed the linked NTIR data and 1+1HS data, calculated influenza notification rates and wrote all drafts of the manuscript. SK contributed to the overall supervision of the development of the paper. SK and YG were investigators on the 1+1HS project. LMcH, SK and YG contributed substantially to the preparation of the data for analysis. SK contributed to data collection. RMA contributed to all drafts of the manuscript, data analysis, influenza notification rates and cross checking results. RW, TS and MJB contributed to the methods, interpretation of results and editing of manuscripts. All authors contributed to and approved the final manuscript. All authors attest they meet the ICMJE criteria for authorship.

# Acknowledgements

We would like to acknowledge the chief investigator team from the original ‘1+1HS’ study, in particular; Professor Lesley Barclay as lead CIA, Dr Sarah Bar Zeev and Dr Cath Josif for data collection and analysis, and Dr Karen Dempsey for assistance with data linkage with the NTIR.

# Author details

Ms Lisa McHugh1

Dr Michael J Binks2

Dr Yu Gao3

Prof Ross M Andrews4

Prof Robert S Ware5

Dr Tom Snelling6

Prof Sue Kildea7

1. PhD scholar, Menzies School of Health Research, Charles Darwin University, Tiwi, Northern Territory, Australia.
2. Senior Research Fellow, Menzies School of Health Research, Charles Darwin University, Tiwi, Northern Territory, Australia.
3. Senior Research Fellow, Mater Midwifery Research Unit – University of Queensland, Women’s Health and Newborn Services (Maternity) Mater Health Service; School of Nursing, Midwifery and Social Work, University of Queensland, Brisbane, Queensland, Australia.
4. Senior Epidemiologist, Menzies School of Health Research, Charles Darwin University, Tiwi, Northern Territory, Australia. Head of Master of Philosophy in Applied Epidemiology Program, National Centre for Epidemiology & Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.
5. Senior Biostatistician, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.
6. Head, Infectious Disease Implementation Research, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia; Perth Children’s Hospital, Perth, Western Australia, Australia; Curtin University, School of Public Health, Perth, Western Australia, Australia.
7. Director, Mater Research Institute – University of Queensland, Women’s Health and Newborn Services (Maternity) Mater Health Service; School of Nursing, Midwifery and Social Work, University of Queensland, Brisbane, Queensland, Australia

## Corresponding author

Dr Lisa McHugh Menzies School of Health Research/Charles Darwin University. Level 1,147 Wharf Street Spring Hill Brisbane QLD, 4000. Telephone: +61 7 418 200 553. Email: lisa.mchugh@menzies.edu.au

# References

1. World Health Organization. Immunization, Vaccines and Biologicals 2016 [Strategic Advisory Group of Experts (SAGE) on Immunization]. Available from: https://www.who.int/immunization/sage\_conclusions/en/index1.html.
2. Pratt R. Pandemic A (H1N1) 2009 influenza-an enhanced hazard during pregnancy. Midwifery. 2010;26(1):13–7.
3. Håberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med. 2013;368(4):333–40.
4. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M, on behalf of UKOSS. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ. 2011;342:d3214.
5. Kelly H, Mercer GN, Cheng A. Quantifying the risk of pandemic influenza in pregnancy and indigenous people in Australia in 2009. Euro Surveill. 2009;14(50). pii: 19441.
6. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 inﬂuenza A(H1N1) infection in Canada. JAMA 2009;302(17):1872–9.
7. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-Etchegorry M, et al. The 2009 pandemic H1N1 inﬂuenza and indigenous populations of the Americas and the Paciﬁc. Euro Surveill. 2009;14(42). pii: 19366.
8. Anzic Influenza Investigators Australasian Maternity Outcomes Surveillance System. Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. BMJ. 2010;340:c1279.
9. Clemens EB, Grant EJ, Wang Z, Gras S, Tipping P, Rossjohn J, et al. Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians. Immunol Cell Biol. 2016;94(4):367–77.
10. Flint SM, Davis JS, Su JY, Oliver-Landry EP, Rogers BA, Goldstein A, et al. Disproportionate impact of pandemic (H1N1) 2009 influenza on Indigenous people in the Top End of Australia’s Northern Territory. Med J Aust. 2010;192(10):617–22.
11. Li-Kim-Moy J. Influenza disease burden in Australia: Influenza Specialist Group Annual Scientific Meeting Feb 5–6, 2017. Available from: http://www.immunisationcoalition.org.au/wp-content/uploads/2017/02/8-Jean-Li-Kim-Moy.pdf
12. Australian Institute of Health and Welfare. Australia’s health 2010. The twelfth biennial health report of the Australian Institute of Health and Welfare. Australian Government, Australian Institute of Health and Welfare,Canberra; 2010.
13. Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H, et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 2006–2010. Commun Dis Intell Q Rep. 2013;37(Suppl.):S1–95.
14. National Notifiable Diseases Surveillance System. Influenza (laboratory confirmed) Public dataset 2008–2016. Australian Government, Department of Health; 2018.
15. National Centre for Immunisation Research and Surveillance. History of immunisation in Australia. National Centre for Immunisation Research and Surveillance, Sydney;2017. Available from: http://www.ncirs.org.au/health-professionals/history-immunisation-australia.
16. O’Grady KA, Dunbar M, Medlin LG, Hall KK, Toombs M, Meiklejohn J, et al. Uptake of influenza vaccination in pregnancy amongst Australian Aboriginal and Torres Strait Islander women: a mixed-methods pilot study. BMC Res Notes. 2015;8(169). https://doi.org/10.1186/s13104-015-1147-3
17. Mak DB, Regan AK, Joyce S, Gibbs R, Effler PV. Antenatal care provider’s advice is the key determinant of influenza vaccination uptake in pregnant women. Aust N Z J Obstet Gynaecol. 2015;55(2):131–7.
18. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government, Department of Health, Canberra, immunisationhandbook.health.gov.au. 10th edition: 2013.
19. Fell DB, Azziz-Baumgartner E, Baker MG, Batra M, Beauté J, Beutels P, et al. Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group. 2017. Vaccine. 2017;35(43):5738–50.
20. Global Advisory Committee on Vaccine Safety. Safety of immunization during pregnancy: a review of the evidence. World Health Organization; 2014.
21. Kildea S, Gao Y, Rolfe M, Josif CM, Bar-Zeev SJ, Steenkamp M, et al. Remote links: redesigning maternity care for Aboriginal women from remote communities in Northern Australia—a comparative cohort study. Midwifery. 2016;34:47–57.
22. Australian Institute of Health and Welfare. Australia’s mothers and babies 2014—in brief. Perinatal statistics series. Australian Government, Australian Institute of Health and Welfare, Canberra; 2016.
23. Wardlaw T, Blanc A, Zupan J, Åhman E. . Low birthweight, country, regional and global estimates. World Health Organization, Unicef;2016. Available from: http://apps.who.int/iris/bitstream/10665/43184/1/9280638327.pdf.
24. Dobbins TA, Sullivan EA, Roberts CL, Simpson JM. Australian national birthweight percentiles by sex and gestational age, 1998–2007. Med J Aust. 2012;197(5):291–4.
25. Kildea SV, Gao Y, Rolfe M, Boyle J, Tracy S, Barclay LM. Risk factors for preterm, low birthweight and small for gestational age births among Aboriginal women from remote communities in Northern Australia. Women Birth. 2017;30(5):398–405.
26. Steenkamp M, Rumbold A, Barclay L, Kildea S. A population-based investigation into inequalities amongst Indigenous mothers and newborns by place of residence in the Northern Territory, Australia. BMC Pregnancy Childbirth. 2012;12:44.
27. Australian Institute of Health and Welfare. Stillbirths in Australia 1991–2009. Australian Government, Australian Institute of Health and Welfare, Canberra; 2014.
28. Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Supp):S1–167.
29. Arnold L, Hoy W, Wang Z. Low birthweight increases risk for cardiovascular disease hospitalisations in a remote Indigenous Australian community—a prospective cohort study. Aust N Z J Public Health. 2016;40(Suppl 1):S102–6.
30. Moberley SA, Lawrence J, Johnston V, Andrews RM. Influenza vaccination coverage among pregnant Indigenous women in the Northern Territory of Australia. Commun Dis Intell Q Rep. 2016;40(3):E340–6.
31. Joseph T, Sinclair M, Menzies R. Vaccination for our mob, 2006–2010. National Centre for Immunisation Research, Sydney;2006.
32. Parkes H. Uptake of influenza vaccination by pregnant women in the Northern Territory. N T Dis Control Bull. 2015;22(4):11–4.
33. Lotter K, Regan AK, Thomas T, Effler PV, Mak DB. Antenatal influenza and pertussis vaccine uptake among Aboriginal mothers in Western Australia. Aust N Z J Obstet Gynaecol. 2018;58(4):417–24.
34. Dunbar M, Moberley S, Nelson S, Leach AJ, Andrews R. Clear not simple: an approach to community consultation for a maternal pneumococcal vaccine trial among Indigenous women in the Northern Territory of Australia. Vaccine. 2007;25(13):2385–8.
35. Dunbar T, Scrimgeour M. Ethics in Indigenous Research – Connecting with Community. J Bioeth Inq. 2006;3(3):179–85.
36. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework. Australian Government, Australian Institute of Health and Welfare, Canberra; 2018.
37. Fell DB, Savitz DA, Kramer MS, Gessner BD, Katz MA, Knight M, et al. Maternal inﬂuenza and birth outcomes: systematic review of comparative studies. BJOG. 2017;124(1):48–59.
38. Nunes MC, Aqil AR, Omer SB, Madhi SA. The effects ofinﬂuenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. Am J Perinatol. 2016;33(11):1104–14.
39. McHugh L, Marshall HS, Perrett KP, Nolan T, Wood N, Lambert SB, et al. The safety of influenza and pertussis vaccination in pregnancy in a cohort of Australian mother-infant pairs, 2012–2015: The FluMum Study. Clin Infect Dis. 2018;68(3):402–8.
40. Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA. 2012;308(2):165–74.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Cindy Toms

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:   
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2019 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>